Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

The first three months of the year weren't nearly as positive as investors had hoped for.

Amgen Reports an Unusual Slide Backward

Amgen earnings of $3.56 per share beat expectations from Wall Street analysts when it reported late Tuesday, though sales were just in line. Amgen stock advanced in after-hours trading.

Biotech Giant Amgen Tops First-Quarter Earnings Forecast, Sales In Line

Shares of Amgen Inc.  rose more than 1% in the extended session Tuesday after the drug company reported adjusted first-quarter profit and sales above expectations.

Amgen stock rises on company's earnings beat, Neulasta sales fall 12%

Amarin Corporation Plc

Exact Sciences

Merck

If you thought Monday was exciting, wait until you see what's on the slate for the rest of the week.

4 More Healthcare Earnings Reports to Watch This Week

The Food and Drug Administration has approved Samsung Bioepis's drug Eticovo as a biosimilar to Amgen Inc.'s  Enbrel, the regulatory agency announced Friday.

FDA approves biosimilar to Amgen's Enbrel

ARK Genomic Revolution Multi-Sector ETF

VanEck Vectors Biotech ETF

Biogen

Bristol-Myers

Celgene

First Trust NYSE Arca Biotechnology Index Fund

Gilead Sciences

iShares Nasdaq Biotechnology ETF

Direxion Daily S&P Biotech Bull 3X Shares

Regeneron Pharmaceuticals

SPDR S&P Biotech ETF

When the stock market is hitting record highs, it’s important to remember that it’s really a market of stocks rather than a stock market. Not all companies are created equal. Nor are all sectors.

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

Abbott Labs

Becton, Dickinson and Co.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Quest Diagnostics

While the overall stock market has been very strong year to date, with sectors like technology outperforming, the health care sector, which encompasses everything from pharmaceuticals to biotech to medical devices and more, has been absolutely wretched, lagging the S&P 500 by a huge 9%.

Why 5 Lagging Health Care Giants May Be Incredible Buys Now

Evenity for building bone mass was approved on April.

Amgen Evenity Approval Just Makes It A Hold

Which biotech giant is the smarter choice for investors today?

Better Buy:  Amgen vs. Gilead Sciences

Shares of Buy-ranked Amgen have declined -1.3% year to date, underperforming the Zacks Biomedical and Genetics industry's increase of +9.3%.

Amgen: Top Analyst Report

NextEra Energy's shares have outperformed the Zacks Electric Power industry in the past year, gaining +18.6% vs. +14.3%.

NextEra Energy: The Zacks Research Daily presents the best research output

Amgen announced late Tuesday the FDA approved Evenity, for treating osteoporosis in postmenopausal women.

Second Time's The Charm For Amgen As FDA OKs Bone-Building Osteoporosis Drug

The U.S. Food and Drug Administration on Tuesday approved Amgen Inc's drug Evenity for the treatment of osteoporosis in postmenopausal women who are at high risk of bone fractures.

FDA approves Amgen's Evenity for treatment of osteoporosis in postmenopausal women

Its size, catalog, and pipeline give it strengths that are hard to beat.

Why Amgen Can Deliver Medical and Financial Miracles

Novartis

These two are intertwined in a legal tango that could get messy.

Why Amgen's Giving Novartis a Headache

Novartis sues Amgen as the latter issues termination notice for migraine drug.

Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig

Amgen has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Amgen is Poised to Beat Earnings Estimates Again

Novartis reportedly sued its partner Amgen on Thursday, accusing the biotech of trying to welsh on their agreement to sell migraine treatment Aimovig. Novartis stock fell more than 1%.

Novartis Lawsuit Accuses Amgen Of Trying To Welsh On Migraine Deal

Axsome Therapeutics

Biogen threw in the towel with once-promising Alzheimer's disease drug aducanumab. But these three late-stage pipeline candidates could potentially still emerge as winners.

3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop

Leading biotech Amgen could expand the market for Repatha by 4.5 million patients with high cholesterol if the PCSK9 inhibitor proves its mettle in a new study, an analyst said Friday.

Can Amgen Leapfrog A Key Rival And Add Millions Of New Patients?

Amgen (AMGN) stock may be a good choice for value-oriented investors right now from multiple angles.

Is Amgen (AMGN) a Profitable Pick ForValue Investors Now?

These cash-flow monsters are trading on the cheap. Which is the better bet for new money today?

News for Amgen Stock (AMGN)